1. Home
  2. STAA vs OMER Comparison

STAA vs OMER Comparison

Compare STAA & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

N/A

Current Price

$17.54

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$11.33

Market Cap

894.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STAA
OMER
Founded
1982
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
894.8M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
STAA
OMER
Price
$17.54
$11.33
Analyst Decision
Hold
Strong Buy
Analyst Count
12
5
Target Price
$23.53
$32.50
AVG Volume (30 Days)
1.4M
2.1M
Earning Date
02-17-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$230,591,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$22.19
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.50
$2.95
52 Week High
$30.81
$17.65

Technical Indicators

Market Signals
Indicator
STAA
OMER
Relative Strength Index (RSI) 25.90 42.33
Support Level $16.94 $10.55
Resistance Level $19.54 $12.18
Average True Range (ATR) 0.78 0.67
MACD -0.11 -0.21
Stochastic Oscillator 12.24 20.66

Price Performance

Historical Comparison
STAA
OMER

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: